Recombinant influenza A/H1N1pdm09 vaccine expressing streptococcal surface epitope for dual protection

Abstract

Aim:Develop A/H1N1pdm09-based live attenuated influenza vaccines (LAIVs) presenting chimeric hemagglutinin (HA) fused to fragments of Streptococcus pneumoniae (PspA, Spr1875) or S. agalactiae (ScaAB) to elicit combined anti-influenza and anti-bacterial immunity.

Methods:Recombinant LAIVs were generated by reverse genetics. Replicative fitness was measured in embryonated chicken eggs (CE; log₁₀EID₅₀/0.1 mL, n = 5 per delution) and MDCK cells (log₁₀TCID₅₀/mL, n = 5). BALB/c mice (n = 20 per group; serology n = 6 per group; lung titers n = 5 per group) received intranasal 10⁶EID₅₀. Systemic IgG and mucosal IgA to influenza and to the recombinant pneumococcal peptide were quantified by ELISA (GMT ± SD). Early cytokine responses were profiled in THP-1 cells.

Results:All recombinant strains replicated in CE at 33°C but were temperature-sensitive at 39°C. H1-ScaAB retained relatively high replication and exhibited a cold-adapted phenotype despite a large N-terminal insert. In MDCK cells, H1-PspA showed significantly reduced replication compared with the parental LAIV. In mouse lungs, replication on day 3 post-immunization was significantly lower for H1-ScaAB and H1-PspA compared with the parental LAIV strain (p < 0.05). The parental LAIV induced robust systemic anti-influenza IgG and, uniquely for H1-ScaAB, significant mucosal anti-influenza IgA ( p < 0.05). H1-Spr generated stronger antibody responses to the inserted pneumococcal peptide ( p < 0.05). THP-1 assays revealed construct-specific cytokine patterns (unmodified H1N1: highest IFN-α; H1-Spr: elevated IL-6; H1-ScaAB: greatest MCP-1).

Conclusions:Multiple A/H1N1pdm09-based recombinant LAIVs with chimeric HA can replicate in eggs and murine respiratory tract and induce dual influenza/pneumococcal antigen responses. Expanded biophysical validation, functional antibody assays and challenge studies are needed to optimize insert design without compromising viral fitness.

Keywords

respiratory infections / vector vaccine / LAIV / chimeric hemagglutinin / pneumococcal vaccination / mucosal immunity

References

[1] McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006; 19: 571-82. [DOI] [PubMed] [PMC]

[2] Miller MR, Peters TR, Suerken CK, Snively BM, Poehling KA. Predictors of Influenza Diagnosis Among Patients With Laboratory-Confirmed Influenza. J Infect Dis. 2015; 212: 1604-12. [DOI] [PubMed] [PMC]

[3] Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019; 23: 258. [DOI] [PubMed] [PMC]

[4] Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013; 9: e1003057. [DOI] [PubMed] [PMC]

[5] van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care. 2010; 14: 219. [DOI] [PubMed] [PMC]

[6] Othumpangat S, Noti JD, McMillen CM, Beezhold DH. ICAM-1 regulates the survival of influenza virus in lung epithelial cells during the early stages of infection. Virology. 2016; 487: 85-94. [DOI] [PubMed] [PMC]

[7] Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, et al. CEACAM1-Mediated Inhibition of Virus Production. Cell Rep. 2016; 15: 2331-9. [DOI] [PubMed] [PMC]

[8] Rowe HM, Meliopoulos VA, Iverson A, Bomme P, Schultz-Cherry S, Rosch JW. Direct interactions with influenza promote bacterial adherence during respiratory infections. Nat Microbiol. 2019; 4: 1328-36. [DOI] [PubMed] [PMC]

[9] Neu U, Mainou BA. Virus interactions with bacteria: Partners in the infectious dance. PLoS Pathog. 2020; 16: e1008234. [DOI] [PubMed] [PMC]

[10] Farrar JL, Childs L, Ouattara M, Akhter F, Britton A, Pilishvili T, et al. Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. Pathogens. 2023; 12: 732. [DOI] [PubMed] [PMC]

[11] Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018; 18: 441-51. [DOI] [PubMed]

[12] Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018; 16: 355-67. [DOI] [PubMed] [PMC]

[13] Peppoloni S, Colombari B, Beninati C, Felici F, Teti G, Speziale P, et al. The Spr1875 protein confers resistance to the microglia-mediated killing of Streptococcus pneumoniae. Microb Pathog. 2013; 59-60: 42-7. [DOI] [PubMed]

[14] Suvorov A, Dukhovlinov I, Leontieva G, Kramskaya T, Koroleva I, Grabovskaya K, et al. Chimeric protein PSPF, a potential vaccine for prevention Streptococcus. Vaccines Vaccin. 2015; 6: 304.

[15] van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis. 2000; 6: 123-32. [DOI] [PubMed] [PMC]

[16] Dotiwala F, Upadhyay AK. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines (Basel). 2023; 11: 1585. [DOI] [PubMed] [PMC]

[17] Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan GF. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines. 2019; 18: 379-92. [DOI] [PubMed]

[18] Isakova-Sivak I, Tretiak T, Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert Rev Vaccines. 2016; 15: 1241-3. [DOI] [PubMed]

[19] Landgraf G, Desheva YA, Rudenko LG. Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines. Virus Res. 2021; 300: 198396. [DOI] [PubMed]

[20] Desheva Y, Rekstin A, Mayorova I, Kopylova N, Kopteva O, Petrachkova D, et al. Biological properties of the recombinant influenza A/H1N1pdm09 virus expressing a fragment of the Streptococcus pneumoniae surface protein. Med Acad J. 2024; 24: 41-50. [DOI]

[21] Cardaci A, Papasergi S, Midiri A, Mancuso G, Domina M, Cariccio VL, et al. Protective activity of Streptococcus pneumoniae Spr1875 protein fragments identified using a phage displayed genomic library. PLoS One. 2012; 7: e36588. [DOI] [PubMed] [PMC]

[22] Swiatlo E, McDaniel LS, Briles DE. Choline-binding proteins. In: Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG, editors. The pneumococcus. Washington, DC: ASM Press; 2004. pp. 49-60. [DOI]

[23] Kramskaya T, Leontieva G, Desheva Y, Grabovskaya K, Gupalova T, Rudenko L, et al. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice. PLoS One. 2019; 14: e0222148. [DOI] [PubMed] [PMC]

[24] Desheva Y, Leontieva G, Kramskaya T, Grabovskaya KB, Karev V, Mamontov A, et al. Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections. PLoS One. 2019; 14: e0218544. [DOI] [PubMed] [PMC]

[25] Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97: 6108-13. [DOI] [PubMed] [PMC]

[26] Okonechnikov K, Golosova O, Fursov M, team U, Varlamov A, Vaskin Y, et al. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012; 28: 1166-7. [DOI] [PubMed]

[27] Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024; 630: 493-500. [DOI] [PubMed] [PMC]

[28] Sehnal D, Bittrich S, Deshpande M, Svobodová R, Berka K, Bazgier V, et al. Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 2021; 49: W431-7. [DOI] [PubMed] [PMC]

[29] Fraczkiewicz R, Braun W. Exact and efficient analytical calculation of the accessible surface areas and their gradients with respect to atomic coordinates: the GETAREA routine. J Comput Chem. 1998; 19: 319-33. [DOI]

[30] Gupta R, Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput. 2002; 310-22. [PubMed]

[31] Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938; 27: 493-7. [DOI]

[32] Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol. 2008; 9: 944-57. [DOI] [PubMed] [PMC]

[33] Böttcher-Friebertshäuser E, Klenk H, Garten W. Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium. Pathog Dis. 2013; 69: 87-100. [DOI] [PubMed] [PMC]

[34] Klenk HD, Garten W. Host cell proteases controlling virus pathogenicity. Trends Microbiol. 1994; 2: 39-43. [DOI] [PubMed]

[35] Kotomina T, Isakova-Sivak I, Matyushenko V, Kim K, Lee Y, Jung Y, et al. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease. Antiviral Res. 2019; 168: 9-17. [DOI] [PubMed] [PMC]

[36] Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, et al. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology. 2004; 324: 67-73. [DOI] [PubMed]

[37] Castrucci MR, Bilsel P, Kawaoka Y. Attenuation of influenza A virus by insertion of a foreign epitope into the neuraminidase. J Virol. 1992; 66: 4647-53. [DOI] [PubMed] [PMC]

[38] Smolonogina TA, Isakova-Sivak IN, Kotomina TS, Evsina AS, Stepanova EA, Prokopenko PI, et al. Generation of a vaccine against group B streptococcal infection on the basis of a cold-adapted influenza A virus. Mol Genet Microbiol Virol. 2019; 34: 25-34. [DOI]

[39] Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012; 486: 420-8. [DOI] [PubMed] [PMC]

[40] Stepanova EA, Isakova-Sivak IN, Matyushenko VA, Matushkina AS, Smolonogina TA, Donina SA, et al. Immunogenicity and protective activity of recombinant influenza viruses expressing fragments of ScaAB lipoprotein of group B streptococci in a mouse model. Med Acad J. 2020; 20: 33-42. [DOI]

[41] Sladkova T, Kostolansky F. The role of cytokines in the immune response to influenza A virus infection. Acta Virol. 2006; 50: 151-62. [PubMed]

[42] Desheva YA, Leontieva GF, Kramskaya TA, Landgraf GO, Sychev IA, Rekstin AR, et al. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection. Heliyon. 2019; 5: e01154. [DOI] [PubMed] [PMC]